Nektar Therapeutics has produced very strong share price gains over the last three years, yet on Simply Wall St’s broader checks it screens as expensive rather than a clear bargain. This puts the recent rally under scrutiny for valuation focused investors.

• The stock has returned roughly 7x over three years, which makes it important to question how much future potential is already reflected in the current share price.
• Expectations around Nektar Therapeutics' ability to translate its pipeline into sustained revenue can support the current valuation, while uncertainty around execution and cash needs may limit how much investors are willing to pay up from here.
• Nektar Therapeutics passes 0 of 6 valuation checks, meaning the wider set of metrics on Simply Wall St suggests the stock leans expensive rather than obviously cheap on fundamentals.

The issue now is whether Nektar Therapeutics' recent gains leave enough valuation headroom to justify taking or maintaining exposure at current levels.

Does Nektar Therapeutics Look Pricey on Sales?

The P/S ratio is a useful way to look at Nektar Therapeutics because the company is still loss making, so earnings based metrics such as P/E are less informative.

Nektar Therapeutics currently trades on a P/S of about 41.5x, which is above both the Pharmaceuticals industry average of around 6.1x and a peer group average near 11.2x. Simply Wall St’s fair P/S ratio for the stock is estimated at roughly 17.5x, based on factors such as its sector, margins, size and risk profile. That fair multiple is less than half of where the shares trade now, indicating a gap between the current price and what the model suggests might be justified by the fundamentals.

This means that a lot of optimism around Nektar Therapeutics’ future revenue potential is already embedded in the share price, and there is limited margin for disappointment if sales do not evolve in line with those expectations.

On the P/S multiple, Nektar Therapeutics currently appears overvalued relative to both its tailored fair ratio and typical industry levels.

The Nektar Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Nektar Therapeutics pick up where the valuation puzzle leaves off. They spell out which assumptions about Nektar Therapeutics' future growth, margins and earnings would need to hold for the stock to be worth materially more or less than its current price. Each narrative focuses on the underlying drivers behind its view of fair value so you can compare those assumptions with how the company actually performs over time on the Community page.

One of the top community narratives on Nektar Therapeutics: 64% undervalued

"Nektar is potentially undervalued due to underappreciation of its underlying T regulatory cell platform, which is supported by deep expertise in PEGylation and immunomodulation…"

Do you think there's more to the story for Nektar Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Nektar Therapeutics, the current picture is that the stock screens as overvalued on market multiples, with a particularly rich P/S ratio relative to both peers and a tailored fair estimate. The broader valuation checks are weak, so the burden of proof now sits with the company to justify this pricing through how its pipeline converts into revenue and, eventually, earnings. The key question for investors is whether Nektar Therapeutics can deliver the commercial traction implied by the current multiple or whether sentiment fades if execution or funding needs fall short of expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.